nach oben

Erschienen in:

01.03.2021 | Solide Tumoren | Leitthema

Fortschrittliche radiologische Diagnostik bei soliden Tumoren im Kindes- und Jugendalter

Staging, Risikostratifizierung und Responsebeurteilung

verfasst von: Prof. Dr. Jürgen Frank Schäfer, Jochen Herrmann, Birgit Kammer, Friederike Koerber, Ilias Tsiflikas, Thekla von Kalle, Hans-Joachim Mentzel

Erschienen in: Die Onkologie | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Das Spektrum solider Tumore bei Kindern und Jugendlichen unterscheidet sich ebenso wie bestimmte Therapieformen (z. B. Knochenmarktransplantationen) von denen des Erwachsenen. Darüber hinaus werden fast alle Patienten in Studien nationaler und internationaler onkologischer Gesellschaften eingeschlossen und in kinderonkologischen Zentren behandelt. Die pädiatrische Radiologie übernimmt hierbei essenzielle Aufgaben, insbesondere bei der therapeutischen Risikostratifizierung und der Therapiekontrolle.

Material und Methoden

Auf der Basis selektiver Literaturrecherche in der Datenbank PubMed, der Leitlinien und Studienprotokollen der nationalen und internationalen Fachgesellschaften wurden die bildgebenden Standards sowie die neuesten Entwicklungen für ausgewählte solide Tumorentitäten beschrieben. Im Einzelnen werden von den in kinderonkologischen Zentren tätigen Autoren embryonale Tumoren, Lymphome. Hirntumoren sowie Tumorprädispositionssyndrome erörtert.

Schlussfolgerung

In der Bildgebung solider Tumore sind sowohl die Durchführung als auch die Beurteilung der Bilddaten bereits relativ standardisiert. Erfahrene Untersucher in zertifizierten Zentren sollten in erster Linie hieran beteiligt sein. Insbesondere die weiteren Innovationen in funktioneller Bildgebung lassen hoffen, dass zukünftig bildgebende Biomarker als Zielparameter in Therapiestudien verwendet werden können.

Mensah J, Jürgens H, Eggert A, Wesselmann S (2017) Zertifizierung Kinderonkologischer Zentren. Forum 32:177–178

Gröbner SN, Worst BC, Weischenfeldt J et al (2018) The landscape of genomic alterations across childhood cancers. Nature 555(7696):321–327PubMed

Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373(24):2336–2346PubMedPubMedCentral

Gatidis S, Bender B, Reimold M, Schäfer JF (2017) PET/MRI in children. Eur J Radiol 94:A64–A70PubMed

Brodeur GM, Pritchard J, Berthold F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466–1477PubMed

Monclair T, Brodeur GM, Ambros PF et al (2009) The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol 27(2):298–303PubMedPubMedCentral

Cohn SL, Pearson AD, London WB et al (2009) The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol 27(2):289–297PubMedPubMedCentral

Sea S (2019) S1-Leitlinie 025-008 Neuroblastom aktueller Stand: 06/2019 LL Neuroblastom (AWMF-Register Nr. 025/008 Klasse: S)

Gassenmaier S, Tsiflikas I, Maennlin S, Urla C, Warmann SW, Schaefer JF (2020) Retrospective accuracy analysis of MRI based lesion size measurement in neuroblastic tumors: which sequence should we choose? BMC Med Imaging 20(1):105PubMedPubMedCentral

10.

Gahr N, Darge K, Hahn G, Kreher BW, von Buiren M, Uhl M (2011) Diffusion-weighted MRI for differentiation of neuroblastoma and ganglioneuroblastoma/ganglioneuroma. Eur J Radiol 79(3):443–446PubMed

11.

Peschmann AL, Beer M, Ammann B et al (2019) Quantitative DWI predicts event-free survival in children with neuroblastic tumours: preliminary findings from a retrospective cohort study. Eur Radiol Exp 3(1):6PubMedPubMedCentral

12.

Brisse HJ, McCarville MB, Granata C et al (2011) Guidelines for imaging and staging of neuroblastic tumors: consensus report from the international neuroblastoma risk group project. Radiology 261(1):243–257PubMed

13.

Kembhavi SA, Rangarajan V, Shah S et al (2014) Prospective observational study on diagnostic accuracy of whole-body MRI in solid small round cell tumours. Clin Radiol 69(9):900–908PubMed

14.

Schaefer JF, Berthold LD, Hahn G et al (2019) Whole-body MRI in children and adolescents—S1 guideline. RoFo 191(7):618–625PubMed

15.

Franzius C, Schmidt M, Hero B, Pfluger T, Hahn K (2008) Procedure guidelines for MIBG-scintigraphy in children. Nuklearmedizin 47(3):132–138PubMed

16.

Li C, Zhang J, Chen S et al (2018) Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma. Eur J Nucl Med Mol Imaging 45(2):306–315PubMed

17.

Bar-Sever Z, Biassoni L, Shulkin B et al (2018) Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging 45(11):2009–2024PubMed

18.

Arumugam S, Manning-Cork NJ, Gains JE, Boterberg T, Gaze MN (2019) The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review. Clin Oncol (R Coll Radiol) 31(3):182–190

19.

Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F (2006) Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease. Strahlenther Onkol 182(7):389–394PubMed

20.

Matthay KK, Villablanca JG, Seeger RC et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s cancer group. N Engl J Med 341(16):1165–1173PubMed

21.

Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F (2010) Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol 74(3):e1–5PubMed

22.

Irtan S, Ehrlich PF, Pritchard-Jones K (2016) Wilms tumor: “state-of-the-art” update, 2016. Semin Pediatr Surg 25(5):250–256PubMed

23.

van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K et al (2017) Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol 14(12):743–752PubMed

24.

Vujanic GM, Gessler M, Ooms A et al (2018) The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol 15(11):693–701PubMedPubMedCentral

25.

AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V) (2016) S1-Leitlinie 025/004: Nephroblastom (Wilms-Tumor)

26.

Watson T, Oostveen M, Rogers H, Pritchard-Jones K, Olsen Ø (2020) The role of imaging in the initial investigation of paediatric renal tumours. Lancet Child Adolesc Health 4(3):232–241PubMed

27.

Schenk JP, Graf N, Günther P et al (2008) Role of MRI in the management of patients with nephroblastoma. Eur Radiol 18(4):683–691PubMed

28.

McDonald K, Duffy P, Chowdhury T, McHugh K (2013) Added value of abdominal cross-sectional imaging (CT or MRI) in staging of Wilms’ tumours. Clin Radiol 68(1):16–20PubMed

29.

Fuchs J, Warmann SW, Szavay P et al (2005) Three-dimensional visualization and virtual simulation of resections in pediatric solid tumors. J Pediatr Surg 40(2):364–370PubMed

30.

Warmann SW, Fuchs J (2019) Technical aspects of nephron-sparing surgery (NSS) in children with bilateral centrally located renal tumors. Semin Pediatr Surg 28(6):150865PubMed

31.

Schenk JP, Schrader C, Zieger B et al (2006) Reference radiology in nephroblastoma: accuracy and relevance for preoperative chemotherapy. RoFo 178(1):38–45PubMed

32.

Littooij AS, Nikkels PG, Hulsbergen-van de Kaa CA, van de Ven CP, van den Heuvel-Eibrink MM, Olsen ØE (2017) Apparent diffusion coefficient as it relates to histopathology findings in post-chemotherapy nephroblastoma: a feasibility study. Pediatr Radiol 47(12):1608–1614PubMedPubMedCentral

33.

Hötker AM, Lollert A, Mazaheri Y et al (2020) Diffusion-weighted MRI in the assessment of nephroblastoma: results of a multi-center trial. Abdom Radiol 45(10):3202–3212

34.

Müller S, Farag I, Weickert J et al (2019) Benchmarking Wilms’ tumor in multisequence MRI data: why does current clinical practice fail? Which popular segmentation algorithms perform well? J Med Imaging 6(3):34001

35.

Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361(17):1662–1670PubMed

36.

Häberle B, Maxwell R, Schweinitz DV, Schmid I (2019) High dose chemotherapy with autologous stem cell transplantation in hepatoblastoma does not improve outcome. Results of the GPOH study HB99. Klin Padiatr 231(6):283–290PubMed

37.

Zsiros J, Brugieres L, Brock P et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14(9):834–842PubMedPubMedCentral

38.

Towbin AJ, Meyers RL, Woodley H et al (2018) 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the paediatric hepatic international tumour trial (PHITT). Pediatr Radiol 48(4):536–554PubMed

39.

Niemeyer C, Eggert A (2018) Pädiatrische Hämatologie und Onkologie, 2. Aufl. https://doi.org/10.1007/978-3-662-43686-8. ISBN 978-3-662-43687‑5CrossRef

40.

Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the children’s hepatic tumors international collaboration. Lancet Oncol 18(1):122–131PubMed

41.

Meyer JS, Siegel MJ, Farooqui SO, Jaramillo D, Fletcher BD, Hoffer FA (2005) Which MRI sequence of the spine best reveals bone-marrow metastases of neuroblastoma? Pediatr Radiol 35(8):778–785PubMed

42.

Weihkopf T, Blettner M, Dantonello T et al (2008) Incidence and time trends of soft tissue sarcomas in German children 1985–2004—a report from the population-based German Childhood Cancer Registry. Eur J Cancer 44(3):432–40. https://doi.org/10.1016/j.ejca.2007.11.013CrossRefPubMed

43.

Inarejos Clemente EJ, Navallas M, Barber Martínez de la Torre I et al (2020) MRI of rhabdomyosarcoma and other soft-tissue sarcomas in children. Radiographics 40(3):791–814PubMed

44.

Vaarwerk B, van der Lee JH, Breunis WB et al (2018) Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: a report from the international society of pediatric oncology malignant Mesenchymal tumor 95 study. Cancer 124(5):1016–1024PubMed

45.

Schoot RA, McHugh K, van Rijn RR et al (2013) Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology 269(3):870–878PubMed

46.

Scheer M, Dantonello T, Brossart P et al (2018) Importance of whole-body imaging with complete coverage of hands and feet in alveolar rhabdomyosarcoma staging. Pediatr Radiol 48(5):648–657PubMed

47.

García-Figueiras R, Baleato-González S, Luna A et al (2020) Assessing immunotherapy with functional and molecular imaging and radiomics. Radiographics 40(7):1987–2010PubMed

48.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA A Cancer J Clin 65(1):5–29

49.

Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068PubMedPubMedCentral

50.

Rosolen A, Perkins SL, Pinkerton CR et al (2015) Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol 33(18):2112–2118PubMedPubMedCentral

51.

Zwarthoed C, El-Galaly TC, Canepari M et al (2017) Prognostic value of bone marrow tracer uptake pattern in baseline PET scans in Hodgkin lymphoma: results from an international collaborative study. J Nucl Med 58(8):1249–1254PubMed

52.

Yağci-Küpeli B, Koçyiğit-Deveci E, Adamhasan F, Küpeli S (2019) The value of 18F-FDG PET/CT in detecting bone marrow involvement in childhood cancers. J Pediatr Hematol Oncol 41(6):438–441PubMed

53.

Bakhshi S, Bhethanabhotla S, Kumar R et al (2017) Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med 58(4):577–583PubMed

54.

Furth C, Amthauer H, Hautzel H et al (2011) Evaluation of interim PET response criteria in paediatric Hodgkin’s lymphoma—results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 22(5):1198–1203PubMed

55.

Gatidis S, Schmidt H, Gucke B et al (2016) Comprehensive oncologic imaging in infants and preschool children with substantially reduced radiation exposure using combined simultaneous (1)(8)F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging: a direct comparison to (1)(8)F-fluorodeoxyglucose positron emission tomography/computed tomography. Invest Radiol 51(1):7–14PubMed

56.

Schafer JF, Gatidis S, Schmidt H et al (2014) Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology 273(1):220–231PubMed

57.

Chawla SC, Federman N, Zhang D et al (2010) Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol 40(5):681–686PubMed

58.

Schäfer JF, Granata C, von Kalle T et al (2020) Whole-body magnetic resonance imaging in pediatric oncology—recommendations by the oncology task force of the ESPR. Pediatr Radiol 50(8):1162–1174PubMedPubMedCentral

59.

Latifoltojar A, Punwani S, Lopes A et al (2019) Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin’s lymphoma: a comparison with multi-modality reference standard including (18)F-FDG-PET-CT. Eur Radiol 29(1):202–212PubMed

60.

Littooij AS, Kwee TC, Barber I et al (2014) Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Eur Radiol 24(5):1153–1165PubMed

61.

Punwani S, Taylor SA, Bainbridge A et al (2010) Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology 255(1):182–190PubMed

62.

Klenk C, Gawande R, Uslu L et al (2014) Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol 15(3):275–285PubMed

63.

Gatidis S, Gueckel B, Reimold M, Pfannenberg C, Tsiflikas I, Schaefer JF (2017) 18F-FDG-PET/MRI for primary staging and therapy response assessment in pediatric oncology: when do we need it and is it sufficient?

64.

Voss SD, Cairo MS (2019) Surveillance imaging in pediatric lymphoma. Pediatr Radiol 49(11):1565–1573PubMed

65.

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

66.

Almansory KO, Fraioli F (2019) Combined PET/MRI in brain glioma imaging. Br J Hosp Med (Lond) 80(7):380–386

67.

Fangusaro J, Witt O, Hernáiz Driever P et al (2020) Response assessment in paediatric low-grade glioma: recommendations from the response assessment in pediatric neuro-oncology (RAPNO) working group. Lancet Oncol 21(6):e305–e16PubMed

68.

Lequin M, Hendrikse J (2017) Advanced MR imaging in pediatric brain tumors, clinical applications. Neuroimaging Clin N Am 27(1):167–190PubMed

69.

Dangouloff-Ros V, Varlet P, Levy R et al (2018) Imaging features of medulloblastoma: conventional imaging, diffusion-weighted imaging, perfusion-weighted imaging, and spectroscopy: from general features to subtypes and characteristics. Neurochirurgie. https://doi.org/10.1016/j.neuchi.2017.10.003CrossRefPubMed

70.

Kikuchi K, Hiwatashi A, Togao O et al (2019) Intravoxel incoherent motion MR imaging of pediatric Intracranial tumors: correlation with histology and diagnostic utility. AJNR Am J Neuroradiol 40(5):878–884PubMedPubMedCentral

71.

Manias KA, Gill SK, MacPherson L et al (2019) Diagnostic accuracy and added value of qualitative radiological review of (1)H-magnetic resonance spectroscopy in evaluation of childhood brain tumors. Neurooncol Pract 6(6):428–437PubMedPubMedCentral

72.

Greer MC (2018) Imaging of cancer predisposition syndromes. Pediatr Radiol 48(9):1364–1375PubMed

73.

Greer MC, Voss SD, States LJ (2017) Pediatric cancer predisposition imaging: focus on whole-body MRI. Clin Cancer Res 23(11):e6–e13PubMed

74.

Kratz CP, Achatz MI, Brugières L et al (2017) Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 23(11):e38–e45PubMed

75.

Ballinger ML, Best A, Mai PL et al (2017) Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol 3(12):1634–1639PubMedPubMedCentral

76.

Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM (2020) Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Skelet Radiol 49(2):199–219

77.

Grasparil AD 2nd, Gottumukkala RV, Greer MC, Gee MS (2020) Whole-body MRI surveillance of cancer predisposition syndromes: current best practice guidelines for use, performance, and interpretation. AJR Am J Roentgenol 215(4):1002–1011PubMed

78.

Schäfer JF, Tsiflikas I, Esser M, Dittmann H, Bender B, Gatidis S (2020) Kombinierte Positronenemissions – Magnetresonanztomographie (PET/MRT) bei Kindern und Jugendlichen. Monatsschr Kinderheilkd. https://doi.org/10.1007/s00112-020-00889-wCrossRef

Titel: Fortschrittliche radiologische Diagnostik bei soliden Tumoren im Kindes- und Jugendalter
Staging, Risikostratifizierung und Responsebeurteilung
verfasst von: Prof. Dr. Jürgen Frank Schäfer
Jochen Herrmann
Birgit Kammer
Friederike Koerber
Ilias Tsiflikas
Thekla von Kalle
Hans-Joachim Mentzel
Publikationsdatum: 01.03.2021
Verlag: Springer Medizin
Schlagwörter: Solide Tumoren
Lymphome
Neuroblastom
Rhabdomyosarkome
Neuroblastom
Erschienen in: Die Onkologie / Ausgabe 5/2021
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-021-00910-1

Springer Medizin

Fortschrittliche radiologische Diagnostik bei soliden Tumoren im Kindes- und Jugendalter

Staging, Risikostratifizierung und Responsebeurteilung